We use cookies to make sure our website better meets your expectations.
You can adjust your web browser's settings to stop accepting cookies. For further information, read our cookie policy.
SEARCH
IN Warsaw
Exchange Rates
Warsaw Stock Exchange - Indices
The Warsaw Voice » National Voice » October 1, 2010
Britain in Poland
You have to be logged in to use the ReadSpeaker utility and listen to a text. It's free-of-charge. Just log in to the site or register if you are not registered user yet.
Pharmaceutical Investor
October 1, 2010   
Article's tools:
Print

GlaxoSmithKline (GSK) is a leading global pharmaceutical company and the biggest investor in its sector in Poland. The company has invested over $400 million in this country since 1998, a sum that includes spending on scientific research, factory modernization, launching advanced process lines and creating new jobs. GlaxoSmithKline employs around 1,850 people in Poland.

Thanks to modernization and improved production process efficiency at GSK’s factory in Poznań, the company has created what is not just one of its own main production and distribution centers but also one of the technologically most advanced factories in Europe. The factory makes more than 160 different medications, and around100 million units leave the Poznań warehouse every year. More than half of these make their way to patients in Poland, while the rest is exported to 80 countries around the world.

Since the start of investment in Poznań, GSK has launched the production of 115 new products. The factory’s rapid development is confirmed by the fact that over the past few years, the production of 44 innovative medications was transferred here from GSK factories in other countries.

In Poland, direct investment means not only GDP growth but also new jobs and transfer of advanced technology, know-how and experience. In view of the potential of Polish science, the company set up its Global IT Center in Poznań, specializing in IT services for all GSK divisions around the world.

GlaxoSmithKline’s potential and its importance for the Polish economy is reflected in its performance in various league tables for 2009, including 29th place in Newsweek magazine’s “100 Most Valuable Polish Companies” (the only pharmaceutical company to make it onto the list) and eighth place in the “500 Most Innovative Companies” table published by the Polish Academy of Sciences’ Institute of Economics.
© The Warsaw Voice 2010-2018
E-mail Marketing Powered by SARE